Evgenyi Shalaev is a notable inventor based in Dana Point, CA (US). He has made significant contributions to the field of pharmaceutical compositions, particularly in the stabilization of Clostridial toxins. With a total of 3 patents to his name, Shalaev continues to push the boundaries of innovation in his area of expertise.

Latest Patents

Shalaev's latest patents focus on non-protein Clostridial toxin compositions. These pharmaceutical compositions are designed to stabilize a Clostridial toxin active ingredient. The compositions can be either liquid or solid and include a surfactant and an antioxidant. In some embodiments, the compositions feature a surfactant selected from poloxamer and polysorbate, along with an antioxidant chosen from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid, and combinations thereof. Additionally, the formulations may optionally include a tonicity agent and/or a lyoprotector, such as trehalose or sucrose.

Career Highlights

Evgenyi Shalaev is currently associated with Allergan, Inc., where he applies his expertise in pharmaceutical innovations. His work has been instrumental in developing new compositions that enhance the efficacy and stability of Clostridial toxins.

Collaborations

Shalaev has collaborated with notable colleagues, including Maurice Abiad and Bhas Dani. These partnerships have contributed to the advancement of his research and the successful development of his patented compositions.

Conclusion

Evgenyi Shalaev is a prominent figure in the field of pharmaceutical innovations, with a focus on Clostridial toxin compositions. His contributions through patents and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.